INmune Bio
Income Statement

Last updated:

Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. INmune Bio's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 59% to $155,000. Profit margin reached -19360%. Total operating expenses were $29,896,000.

Profit Margin

INmune Bio, Inc. (NASDAQ:INMB): Profit margin
2015 0 -48.86K
2016 0 -277.49K
2017 0 -831.48K
2018 0 -12.44M
2019 77.68M -9.14M -11.77%
2020 10.91K -12.09M -110838.76%
2021 181K -30.34M -16762.43%
2022 374K -28.64M -7659.63%
2023 155K -30.00M -19360%

INMB Income Statement (2015 – 2023)

2023 2022 2021 2020 2019 2018 2017 2016 2015
Revenue
Revenue
155K374K181K10.91K77.68M0000
Cost of revenue
000000000
Gross profit
155K374K181K10.91K77.68M0000
Operating exp.
Research and development
20.27M17.06M20.54M5.91M3.28M1.10M435.36K101.49K0
Selling and marketing
00000000-146.60K
Total operating expenses
29.89M26.32M29.33M12.23M9.29M12.44M981.48K227.49K48.86K
Operating income
-29.74M-25.95M-29.15M-12.22M-7.75M-12.44M-981.48K-227.49K-48.87K
Other income (expenses), net
-267K-1.34M-1.18M129K77.68K0149.99K-50K0
Income before tax
-30.00M-27.29M-30.34M-12.09M-7.67M-12.44M-831.48K-277.49K-48.86K
Income tax expense
01.34M-29.15M-12.22M1.46M0-1.13M00
Net income
-30.00M-28.64M-30.34M-12.09M-9.14M-12.44M-831.48K-277.49K-48.86K
Earnings per share
Basic EPS
-1.67-1.6-1.88-1.01-0.89-1.11-0.07-0.02-0.00
Diluted EPS
-1.67-1.6-1.88-1.01-0.89-1.11-0.07-0.02-0.00
Data sourceData sourceData sourceData sourceData sourceData source